The reduced OS associated with FLT3-D835 mutations in APL patients demonstrated in the present study was not previously confirmed among non-promyelocytic AML [7], suggesting that these mutations play different roles in these leukemia subtypes. This evidence concerns the gene FLT3 and leukemia.